

Amendments to the Specification:

Please amend the specification on page 11, paragraph 5, through page 2, paragraph 1, as follows:

Generally, an LNA oligonucleotide sequence 110 will be chosen that is complementary to the target SSR 120 to be captured. For example, if the target SSR 120 has a nucleotide sequence of 5' -(CA)₆- 3' (SEQ ID NO:1), a preferred LNA oligonucleotide sequence 110 would be 3'-(GT)₆- 5' (SEQ ID NO:2). Alternatively, the complementary sequence in the target dsDNA could be targeted by a complementary LNA sequence). However, because strand recognition permits some degree of mismatch, each LNA oligonucleotide 107 need not correspond exactly to each SSR nucleotide according to its Watson-Crick pairing. Any LNA oligonucleotide sequence 110 which will selectively bind to a target SSR sequence 120 is contemplated within the present invention. LNA oligonucleotides sequences 110 may be obtained commercially from Proligo, LLC (Boulder, CO). Alternatively, LNA oligonucleotide sequences 110 may be synthesized according to the methods described in PCT WO 99/14226, or by any other methods known to those skilled in the art of synthesizing modified oligonucleotide sequences.

Amendments to the drawings:

Please amend Figure 1 to include SEQ ID NOS: 3, 4 and 5, and as indicated on the attached "Annotated Sheet Showing Changes" and the Replacement Sheet.